Investor Relations

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel medicines for the management of central nervous system (CNS) disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our pipeline includes two late-stage product candidates, AXS-02 and AXS-05, which we are developing for multiple indications.

NASDAQ AXSM (Common Stock) $2.45 + 0.15 (6.52%)
Stock chart for: AXSM.O.  Currently trading at $2.45 with a 52 week high of $6.45 and a 52 week low of $2.05.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update

August 8, 2018Interim analysis results from two Phase 3 trials and topline results from one Phase 2 trial of AXS-05 anticipated in 4Q 2018 Phase 3 trial of AXS-07 in acute migraine anticipated to start in 4Q 2018 Phase 2 results of AXS-05 in smoking cessation anticipated in 1Q 2019 Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 08, 2018 (GLOBE NEWSWIRE) --  Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the ma... 

Axsome Therapeutics to Report Second Quarter 2018 Financial Results on August 8, 2018

August 1, 2018Axsome to host conference call and webcast on Wednesday, August 8, 2018 at 8:00 AM Eastern Time NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter of 2018 on Wednesday, August 8, 2018 before the opening of the U.S. financial markets. Axsome’s manage... 

Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer’s Association International Conference

July 17, 2018NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a poster presentation on AXS-05 at the 2018 Alzheimer’s Association International Conference (AAIC) on July 23, 2018 in Chicago, IL. AXS-05 is a novel, oral, investigational medicine consisting of dextromethorphan and bupropion, in late-stage development for the tr...